NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.17

+0.10 (+4.83%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.05
▼
$2.20
50-Day Range: $1.89
▼
$2.56
52-Week Range: $1.31
▼
$4.72

Volume: 234,085 shs
Average Volume: 864,450 shs
Market Capitalization: $409.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 591.2% Upside
$15.00 Price Target
Short Interest: Healthy
2.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.60) to ($0.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

807th out of 1,022 stocks

Pharmaceutical Preparations Industry

394th out of 499 stocks

3.5

Analyst's Opinion

Consensus Rating
Lexicon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Lexicon Pharmaceuticals has a forecasted upside of 591.2% from its current price of $2.17.
Amount of Analyst Coverage
Lexicon Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.05% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Lexicon Pharmaceuticals has recently decreased by 9.39%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Lexicon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Lexicon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LXRX.

1.5

News and Social Media Coverage

News Sentiment
Lexicon Pharmaceuticals has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
Search Interest
Only 6 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
4 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Lexicon Pharmaceuticals is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Lexicon Pharmaceuticals are expected to decrease in the coming year, from ($0.60) to ($0.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lexicon Pharmaceuticals is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lexicon Pharmaceuticals is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lexicon Pharmaceuticals has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

November 30, 2022 | americanbankingnews.com

StockNews.com Lowers Lexicon Pharmaceuticals (NASDAQ:LXRX) to Sell

November 28, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference

November 15, 2022 | finance.yahoo.com

Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

November 12, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 11, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

November 10, 2022 | markets.businessinsider.com

Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham

November 10, 2022 | seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript

November 9, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

November 8, 2022 | msn.com

Earnings Outlook For Lexicon Pharmaceuticals

November 8, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit

November 6, 2022 | benzinga.com

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 6, 2022 | finance.yahoo.com

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 5, 2022 | benzinga.com

New Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

November 5, 2022 | finance.yahoo.com

New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

November 4, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

October 31, 2022 | finance.yahoo.com

New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022

October 24, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

October 2, 2022 | benzinga.com

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events

October 2, 2022 | finance.yahoo.com

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

September 20, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

September 14, 2022 | msn.com

Bridgewater becomes home to another pharmaceutical company

September 9, 2022 | uk.finance.yahoo.com

Lexicon Pharmaceuticals, Inc. (LXRX)

August 22, 2022 | finance.yahoo.com

Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease

August 12, 2022 | seekingalpha.com

Lexicon adds 15% as Piper Sandler sees “blockbuster potential” for key assets

August 5, 2022 | finance.yahoo.com

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings: 11/03/2021
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:LXRX
Previous Symbol: NASDAQ:LEXG
CUSIP: 52887210
CIK: 1062822
Web: www.lexpharma.com
Phone: (281) 863-3000
Fax: 281-863-8010
Employees: 87
Year Founded: 1995

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +360.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,760,000.00
Net Margins: -77,648.80%
Pretax Margin: -77,648.80%
Return on Equity: -92.19%
Return on Assets: -67.28%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 7.54
Quick Ratio: 7.54

Sales & Book Value

Annual Sales: $300,000.00
Price / Sales: 1,365.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.76 per share
Price / Book: 2.86

Miscellaneous

Outstanding Shares: 188,726,000
Free Float: 176,459,000
Market Cap: $409.54 million
Optionable: Optionable
Beta: 1.34

Social Links

Key Executives

Mr. Lonnel Coats (Age 57)
CEO & Director
Comp: $1.14M

Mr. Jeffrey L. Wade J.D. (Age 57)
Pres & CFO
Comp: $718.14k

Mr. Brian T. Crum (Age 49)
Sr. VP, Gen. Counsel & Sec.
Comp: $557.49k

Dr. Alan J. Main Ph.D. (Age 68)
Exec. VP of Innovation & Chemical Sciences
Comp: $574.2k

Dr. Craig B. Granowitz M.D. (Age 57)
Ph.D., Sr. VP & Chief Medical Officer
Comp: $450.46k

Dr. Robert J. Lefkowitz M.D. (Age 78)
Consultant & Independent Director
Comp: $50k

Ms. Kristen L. Alexander (Age 54)
VP of Fin. & Accounting

Mike Kelly
Investor Relations Officer

Chas Schultz
Exec. Director of Corp. Communications & Patient Advocacy

Ms. Wendy E. McDermott (Age 51)
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings or view top-rated stocks.
What is Lexicon Pharmaceuticals' stock price forecast for 2023?: 2 brokers have issued 1-year target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 591.2% from the stock's current price.
View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts.
How have LXRX shares performed in 2022?: Lexicon Pharmaceuticals' stock was trading at $3.94 at the start of the year. Since then, LXRX stock has decreased by 44.9% and is now trading at $2.17.
View the best growth stocks for 2022 here.
When is Lexicon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our LXRX earnings forecast.
How were Lexicon Pharmaceuticals' earnings last quarter?: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative net margin of 77,648.80% and a negative trailing twelve-month return on equity of 92.19%. During the same period in the prior year, the business earned $0.71 EPS.
What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?: 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).
What is Lexicon Pharmaceuticals' stock symbol?: Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
Who are Lexicon Pharmaceuticals' major shareholders?: Lexicon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.56%), BlackRock Inc. (3.05%), Vanguard Group Inc. (2.79%), Point72 Asset Management L.P. (1.91%), Pinnacle Associates Ltd. (1.11%) and State Street Corp (0.78%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends.
How do I buy shares of Lexicon Pharmaceuticals?: Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lexicon Pharmaceuticals' stock price today?: One share of LXRX stock can currently be purchased for approximately $2.17.
How much money does Lexicon Pharmaceuticals make?: Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $409.54 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-87,760,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.
How can I contact Lexicon Pharmaceuticals?: Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial